AstraZeneca to Acquire Icosavax, in-development RSV-hMPV Combo Vaccine
AstraZeneca has entered into a definitive agreement to acquire Icosavax Inc and its combination vaccine candidate for RSV and hMPV.
AstraZeneca has entered into a definitive agreement to acquire Icosavax Inc and its combination vaccine candidate for RSV and hMPV.
AstraZeneca has entered into a definitive agreement to acquire Icosavax Inc and its combination vaccine candidate for RSV and hMPV.
Read MoreA team of molecular and structural biologists from Nanyang Technological University, Singapore (NTU Singapore) have found a potential new route to disabling respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) after elucidating the structure of one of its key components.
Read MoreNew data shows that human metapneumovirus demonstrated seasonality by beginning in the winter and lasting until spring when compared with influenza and RSV.
Read More